| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S40261-016-0466-Z |
| P698 | PubMed publication ID | 27718163 |
| P50 | author | Sohita Dhillon | Q102146188 |
| P2860 | cites work | Long-term opioid management for chronic noncancer pain | Q24240811 |
| Opioid Abuse in Chronic Pain--Misconceptions and Mitigation Strategies | Q26749305 | ||
| Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain | Q33705809 | ||
| Opioids for chronic noncancer pain: a position paper of the American Academy of Neurology | Q34441004 | ||
| Efficacy, Tolerability, and Dose-Dependent Effects of Opioid Analgesics for Low Back Pain: A Systematic Review and Meta-analysis | Q34527883 | ||
| Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendations | Q35846608 | ||
| Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations | Q37616606 | ||
| Challenges in design and interpretation of chronic pain trials. | Q38116498 | ||
| Zohydro approval by food and drug administration: controversial or frightening? | Q38233083 | ||
| Pharmacokinetic Profile and Sustained 24-hour Analgesia of a Once-daily Hydrocodone Bitartrate Extended-release Tablet with Abuse-deterrent Properties | Q38397474 | ||
| CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. | Q38778400 | ||
| Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain | Q38799636 | ||
| Chronic Pain and the Opioid Conundrum | Q38840683 | ||
| Efficacy and Safety of Once-Daily Extended-Release (ER) Hydrocodone in Individuals Previously Receiving ER Morphine for Chronic Pain | Q38868842 | ||
| 12-Month safety and effectiveness of once-daily hydrocodone tablets formulated with abuse-deterrent properties in patients with moderate to severe chronic pain | Q39184237 | ||
| Efficacy and safety of once-daily, extended-release hydrocodone in individuals previously receiving hydrocodone/acetaminophen combination therapy for chronic pain | Q39196945 | ||
| Pain intensity and interference with functioning and well-being in subgroups of patients with chronic pain treated with once-daily hydrocodone tablets | Q40147876 | ||
| Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale | Q40678235 | ||
| A multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of single-entity, once-daily hydrocodone tablets in patients with uncontrolled moderate to severe chronic low back pain | Q40797006 | ||
| Basic opioid pharmacology: an update | Q41527971 | ||
| Intranasal Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users | Q42357273 | ||
| Removal of opioid/acetaminophen combination prescription pain medications: assessing the evidence for hepatotoxicity and consequences of removal of these medications | Q43071881 | ||
| Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010. | Q44161409 | ||
| Oral Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users | Q44340250 | ||
| Food and Drug Administration Requires Strong Warnings for Opioid Analgesics, Prescription Opioid Cough Products, and Benzodiazepine Labeling Related to Serious Risks and Death From Combined Use. | Q44341958 | ||
| Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment | Q46716773 | ||
| Long-term safety and effectiveness of once-daily, single-entity, extended-release hydrocodone over 76 weeks of an open-label study in patients with chronic noncancer and nonneuropathic pain | Q47908326 | ||
| Individualized Hydrocodone Therapy Based on Phenotype, Pharmacogenetics, and Pharmacokinetic Dosing. | Q51014657 | ||
| Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet | Q86092031 | ||
| P433 | issue | 11 | |
| P921 | main subject | chronic pain | Q1088113 |
| P304 | page(s) | 969-980 | |
| P577 | publication date | 2016-10-07 | |
| P1433 | published in | Clinical Drug Investigation | Q15753215 |
| P1476 | title | Hydrocodone Bitartrate ER (Hysingla® ER): A Review in Chronic Pain | |
| P478 | volume | 36 |
Search more.